Tuesday, December 2, 2014

Anyone want to respond to this comment?


 Anonymous said...
why wont this die. I have been reading about this incident with NECC everyday all these years. I agree that this is a misfortunate incident that should have never been allowed to happen. But , it dide and for God's sake Lets move on. Compounders are facing a huge issue right now with PBM's. Hey Markey !? lets talk about Express Scripts and big Pharma!
December 2, 2014 at 11:53 AM
 Delete
Anonymous Anonymous said...
You do realize this is a flashback that is probably meant to give compounders an idea of why the DEA may be inspecting them.
December 2, 2014 at 1:25 PM


 DeleteAnonymous said...
The incident with NECC is a sentinel event--immortalized like other public health disasters--it is tip-of-the-iceberg for a practice area that otherwise escapes our surveillance and may buried in background. Exposed patients continue to be at risk, and those that have diagnosed morbidity are in a chronic disease state. We should continue follow-up.

[excerpt]
In a December 2013 “lessons learned” opinion, Pappas noted that while the overall (known) mortality associated with the outbreak remains low, “morbidity relating to persistent symptoms and treatment associated toxicity is high”71 indicating that clinical manifestations of the early outbreak have shifted to a less-well characterized, chronic disease setting. The overall cost to human health caused by the 2012 outbreak is immeasurable, as is the total financial impact to healthcare systems. For a single hospital health system, the identification of particulate in an outsourced compounded product triggered an investigation costing nearly 1 million dollars for 5 lots of compounded medication totaling 1090 units, at an added cost of $802.74 per unit purchased.72 The research letter notes “Fungal contamination of MgSO4 required extensive pharmacy, laboratory, infection control, and hospital administrative support; substantial hospital resources for patient and physician notification; ongoing surveillance; and prophylactic treatment of high-risk patients”.72 Remarkably, as the early publications on the outbreak were being published, pharmacies that would later recall products due to identified contamination or lack of assurance of sterility continued to supply the market with non-FDA approved medicines for sterile use, including methylprednisolone acetate suspension.


See submission at http://www.regulations.gov/#!documentDetail;D=FDA-2013-N-1523-0006

1 comment:

Pharmacist Steve said...

IMO... this is being used as a reason to federalize all of pharmacy.. just look at the advantage that NACDS and its members would have if both Pharmacists and stores were licensed at the Federal level.. and they could not have to bother with lobbying the various state legislatures and focus all their lobbying money on Congress. The "bad outcomes" for everyone except the corporations is endless